3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
11
Terminated
5
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia, Lymphocytic, Chronic, B-Cell
2
Recurrence
1
Prostatic Neoplasms
1
Philadelphia Chromosome
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia
1
Hematologic Neoplasms
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
Paclitaxel
28
Trastuzumab
22
Cyclophosphamide
21
Doxorubicin
14
Docetaxel
14
Carboplatin
11
exemestane
10
Radiotherapy
10
Letrozole
10
Capecitabine
10
pembrolizumab
8
Lapatinib
8
Fulvestrant
8
Neoadjuvant Therapy
6
Goserelin
6
Bevacizumab
6
Anastrozole
6
pertuzumab
5
palbociclib
5
eribulin
5
abemaciclib
5
Therapeutics
5
Magnetic Resonance Spectroscopy
5
Epirubicin
5
Chemotherapy, Adjuvant
5
Aromatase Inhibitors
5
tucatinib
4
Vinorelbine
4
Taxes
4
Tamoxifen
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Breast Neoplasms
×
Dasatinib
×
Clear all
NCT01410708
2016-02-17
TORI 104 Pre-Surgical Dasatinib
AHS Cancer Control Alberta
Phase 2
Withdrawn